Laxogenin vs Ostarine

Laxogenin wins for minimal suppression, non-hormonal profile, and lower side-effect risk. It's the safest bridge or add-on for recovery and mild recomp, non-toxic even with extended research periods, and legal in most jurisdictions.

Ostarine wins for clinically-backed potency in lean mass retention during a cut, true AR-mediated protein synthesis, and reliable muscle preservation in a calorie deficit. It's the more powerful option when preservation or slight gain are mission-critical — but with HPTA suppression and more pronounced lipid effects, cycles should be structured carefully.

Pick Laxogenin if:

• Sourcing or research context requires staying fully non-suppressive
• Recovery and mild recomp are priority without triggering HPTA shutdown
• Bridging between cycles, or stacking on TRT with no added suppression risk
• Side-effect avoidance (no estrogen, DHT, or liver stress)
• Legal status of SARMs/SARM analogs is a limiting factor

Pick Ostarine if:

• Preserving lean mass during an aggressive cut is a must
• Enhanced recomp is the goal and moderate HPTA suppression is acceptable
• Research protocol requires clinically proven anabolic/anticatabolic effect
• Maximizing efficiency when bridging between harsher cycles
• A well-documented SARM with predictable dose-response is preferred